Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas

DOI: 10.1016/j.ijrobp.2008.08.070
International Journal of Radiation Oncology Biology Physics, 2009, 74, 824-30.

#	Paper	IF	Citations
385	IMRT, RapidArc and conformal radiotherapy in the treatment of tumours of the anal canal. **2014**, 8, 469		7
384	A fast radiotherapy paradigm for anal cancer with volumetric modulated arc therapy (VMAT). *Radiation Oncology*, **2009**, 4, 48	4.2	31
383	[Help for delineation: what kind of tools?]. *Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique*, **2009**, 13, 600-5	1.3	3
382	Target volume shape variation during irradiation of rectal cancer patients in supine position: comparison with prone position. **2009**, 93, 285-92		36
381	Geographic miss in radiation oncology: have we missed the boat?. **2009**, 53, 506-9		4
380	Combined modality therapy for rectal cancer. **2010**, 16, 253-61		18
379	Radiation therapy advances for treatment of anal cancer. **2010**, 8, 123-9		21
378	Radiation therapy for rectal cancer: current status and future directions. **2010**, 17, 25-34		14
377	Local Pelvic Relapses after Neoadjuvant High-dose Rate Endorectal Brachytherapy for Patients with Operable Rectal Cancer. **2010**, 6, 228-234		1
376	Current and emerging treatment strategies for anal cancer. **2010**, 12, 168-74		9
375	Impact of neoadjuvant chemoradiation on pathologic response and survival of patients with locally advanced rectal cancer. **2010**, 15, 51-9		11
374	Squamous cell carcinoma of the anal canal: patterns and predictors of failure and implications for intensity-modulated radiation treatment planning. *International Journal of Radiation Oncology Biology Physics*, **2010**, 78, 1064-72	4	58
373	FDG-PET/CT imaging for staging and target volume delineation in conformal radiotherapy of anal carcinoma. *Radiation Oncology*, **2010**, 5, 10	4.2	60
372	Target volume delineation for preoperative radiotherapy of rectal cancer: inter-observer variability and potential impact of FDG-PET/CT imaging. **2010**, 9, 393-8		29
371	Contrast media use in radiation oncology: a prospective, controlled educational intervention study with retrospective analysis of patient outcomes. **2010**, 7, 967-74		2
370	A consensus-based guideline defining the clinical target volume for pelvic lymph nodes in external beam radiotherapy for uterine cervical cancer. **2010**, 40, 456-63		68
369	Tools for consensus analysis of experts' contours for radiotherapy structure definitions. **2010**, 97, 572-8		77

368	The role of adaptive and functional imaging modalities in radiation therapy: approach and application from a radiation oncology perspective. **2010**, 31, 444-61		6
367	[Rectal cancer]. *Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique*, **2010**, 14 Suppl 1, S111-9	1.3	2
366	Chemoradiation for rectal cancer: rationale, approaches, and controversies. **2010**, 19, 803-18		4
365	Adjuvant radiotherapy for rectal cancer: recent results, new questions. **2011**, 35, 17-22		4
364	Comparative analysis of volumetric modulated arc therapy versus intensity modulated radiation therapy for radiotherapy of anal carcinoma. *Practical Radiation Oncology*, **2011**, 1, 163-72	2.8	7
363	Rectal and bladder deformation and displacement during preoperative radiotherapy for rectal cancer: Are current margin guidelines adequate for conformal therapy?. *Practical Radiation Oncology*, **2011**, 1, 85-94	2.8	12
362	Progress in the treatment of locally advanced clinically resectable rectal cancer. *Clinical Colorectal Cancer*, **2011**, 10, 227-37	3.8	10
361	[Rectal cancer: The radiation basis of radiotherapy, target volume]. *Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique*, **2011**, 15, 431-5	1.3	1
360	[Intensity-modulated radiation therapy for anal carcinoma]. *Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique*, **2011**, 15, 549-54	1.3	1
359	T1-2 anal carcinoma requires elective inguinal radiation treatment--the results of Trans Tasman Radiation Oncology Group study TROG 99.02. **2011**, 98, 93-8		34
358	Cancers of the Colon, Rectum, and Anus. *Medical Radiology*, **2011**, 777-799	0.2	
357	Normal tissue dose conformality measures to guide radiotherapy fractionation decisions. **2011**, 38, 1799-805		9
356	Unique considerations in the patient with rectal cancer. **2011**, 38, 542-51		16
355	One Size Does Not Fit All: Planning Volumes for Radiotherapy in Rectal CancerShould We Tailor Radiotherapy Fields to Stage and Risk?. **2011**, 7, 89-96		
354	Update on treatment advances in combined-modality therapy for anal and rectal carcinomas. **2011**, 13, 177-85		8
353	Intensity modulated radiation therapy (IMRT): differences in target volumes and improvement in clinically relevant doses to small bowel in rectal carcinoma. *Radiation Oncology*, **2011**, 6, 63	4.2	63
352	Prospective randomized double-blind pilot study of site-specific consensus atlas implementation for rectal cancer target volume delineation in the cooperative group setting. *International Journal of Radiation Oncology Biology Physics*, **2011**, 79, 481-9	4	67
351	Three-dimensional analysis of recurrence patterns in rectal cancer: the cranial border in hypofractionated preoperative radiotherapy can be lowered. *International Journal of Radiation Oncology Biology Physics*, **2011**, 80, 103-10	4	53

350	Anal cancer: an examination of radiotherapy strategies. *International Journal of Radiation Oncology Biology Physics*, **2011**, 79, 1290-301	4	15
349	Thymidylate synthase genotype-directed neoadjuvant chemoradiation for patients with rectal adenocarcinoma. *Journal of Clinical Oncology*, **2011**, 29, 875-83	2.2	52
348	Methylenetetrahydrofolate reductase genetic polymorphisms and toxicity to 5-FU-based chemoradiation in rectal cancer. **2011**, 105, 1654-62		37
347	Intensity-modulated radiation therapy for rectal carcinoma can reduce treatment breaks and emergency department visits. **2012**, 2012, 891067		22
346	Role of radiotherapy for resectable rectal cancer. **2012**, 1, 413-422		
345	What Is the Role of IMRT and IGRT in Rectal Cancer?. **2012**, 129-148		
344	Should We Tailor the Delineation of Pelvic Structures According to Tumor Presentation?. **2012**, 117-127		
343	Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy. *International Journal of Radiation Oncology Biology Physics*, **2012**, 82, 153-8	4	133
342	Australasian Gastrointestinal Trials Group (AGITG) contouring atlas and planning guidelines for intensity-modulated radiotherapy in anal cancer. *International Journal of Radiation Oncology Biology Physics*, **2012**, 83, 1455-62	4	120
341	Chemoradiotherapy of anal carcinoma: survival and recurrence in an unselected national cohort. *International Journal of Radiation Oncology Biology Physics*, **2012**, 83, e173-80	4	35
340	Target volume delineation variation in radiotherapy for early stage rectal cancer in the Netherlands. **2012**, 102, 14-21		49
339	Performance of an atlas-based autosegmentation software for delineation of target volumes for radiotherapy of breast and anorectal cancer. **2012**, 102, 68-73		65
338	The therapeutic and adverse effects of modified radiation fields for patients with rectal cancer. *Clinical Colorectal Cancer*, **2012**, 11, 255-62	3.8	2
337	Evaluation of variability in seroma delineation between clinical specialist radiation therapist and radiation oncologist for adjuvant breast irradiation. *Practical Radiation Oncology*, **2012**, 2, 114-21	2.8	14
336	Contouring inguinal and femoral nodes; how much margin is needed around the vessels?. *Practical Radiation Oncology*, **2012**, 2, 274-278	2.8	25
335	Clinical target volumes in anal cancer: calculating what dose was likely to have been delivered in the UK ACT II trial protocol. **2012**, 103, 341-6		10
334	Categorizing segmentation quality using a quantitative quality assurance algorithm. **2012**, 56, 668-78		4
333	Squamous-cell carcinoma of the anal canal: room for improvement with targeted therapy. **2012**, 36, 209-13		4

332	Comparison of neoadjuvant oral chemotherapy with UFT plus Folinic acid or Capecitabine concomitant with radiotherapy on locally advanced rectal cancer. **2012**, 17, 376-83		1
331	Radiochemotherapie des Analkarzinoms. **2012**, 18, 672-677		1
330	ACR appropriateness criteria resectable rectal cancer. *Radiation Oncology*, **2012**, 7, 161	4.2	20
329	Stereotactic body radiation therapy for abdominal oligometastases: a biological and clinical review. *Radiation Oncology*, **2012**, 7, 126	4.2	31
328	Outcomes of anal cancer treated with definitive IMRT-based chemoradiation. **2012**, 1, 165-172		8
327	Do We Need Intensity-Modulated Radiation Therapy (IMRT) Routinely in the Preoperative Setting for Rectal Cancer?. **2012**, 8, 99-104		
326	Image-guided radiotherapy for rectal cancer: a systematic review. **2012**, 24, 250-60		20
325	Imaging for target volume delineation in rectal cancer radiotherapy--a systematic review. **2012**, 24, 52-63		31
324	Using kV-kV and CBCT imaging to evaluate rectal cancer patient position when treated prone on a newly available belly board. *Medical Dosimetry*, **2012**, 37, 117-21	1.3	8
323	Dosimetric impact of inter-observer variability for 3D conformal radiotherapy and volumetric modulated arc therapy: the rectal tumor target definition case. *Radiation Oncology*, **2013**, 8, 176	4.2	19
322	Anal cancer: are we making progress?. **2013**, 15, 170-81		9
321	Radiochemotherapie des Analkarzinoms. **2013**, 35, 177-181		
320	Target Volume Definition in Rectal Cancer: What Is the Best Imaging Modality?. **2013**, 9, 116-125		
319	[Guidelines for delineation of pelvic lymph nodes in anal cancer treatment]. *Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique*, **2013**, 17, 566-70	1.3	1
318	Current treatment of rectal cancer adapted to the individual patient. **2013**, 18, 353-62		10
317	Challenges in the neoadjuvant treatment of rectal cancer: balancing the risk of recurrence and quality of life. *Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique*, **2013**, 17, 675-85	1.3	25
316	Rectal and Anal Cancer. *Medical Radiology*, **2013**, 167-184	0.2	
315	[Preoperative radiotherapy for rectal cancer: target volumes]. *Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique*, **2013**, 17, 477-85	1.3	5

314	Anal Canal Cancer. **2013**, 169-175		
313	Rectal Cancer. **2013**, 161-168		1
312	Neoadjuvant oral vs. infusional chemoradiotherapy on locally advanced rectal cancer: Prognostic factors. **2012**, 18, 67-75		4
311	Intensity-modulated radiotherapy in anal cancer: where do we go from here?. **2013**, 25, 153-4		6
310	The Red Journal's most downloaded articles of 2012. *International Journal of Radiation Oncology Biology Physics*, **2013**, 86, 218-21	4	2
309	Favorable anal cancer: does it include T2N0 disease? How might the electively irradiated nodal volume be reduced?. *International Journal of Radiation Oncology Biology Physics*, **2013**, 87, 13-5	4	1
308	RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. *International Journal of Radiation Oncology Biology Physics*, **2013**, 86, 27-33	4	396
307	RTOG 0529: Intensity modulated radiation therapy and anal cancer, a step in the right direction?. *International Journal of Radiation Oncology Biology Physics*, **2013**, 86, 8-10	4	11
306	Integrated peripheral boost in preoperative radiotherapy for the locally most advanced non-resectable rectal cancer patients. **2013**, 52, 528-37		25
305	Acute effects of pelvic irradiation on the adult uterus revealed by dynamic contrast-enhanced MRI. **2013**, 86, 20130334		9
304	Radiotherapy planning at rectal cancer. **2013**, 28, 91-99		
303	Neoadjuvant short-course hyperfractionated accelerated radiotherapy (SC-HART) combined with S-1 for locally advanced rectal cancer. **2013**, 54, 1118-24		12
302	Quality assurance for radiotherapy: a priority for clinical trials. **2013**, 105, 376-7		16
301	Clinical relevance of positron emission tomography/computed tomography-positive inguinal nodes in rectal cancer after neoadjuvant chemoradiation. **2013**, 15, 674-82		7
300	Sphincter preservation in anal cancer: a brief review. **2013**, 19, 101-7		1
299	Clinical application of multimodality imaging in radiotherapy treatment planning for rectal cancer. **2013**, 13, 495-501		6
298	Is Two-Dimensional Field Definition Sufficient for Pelvic Node Coverage in Rectal Cancer Compared to Technical Three-Dimensional Definition?. **2013**, 99, 191-198		0
297	Chemoradiotherapy for anal cancer: clinical trials past, present and future. **2014**, 3, 289-297		

296	Dosimetric coverage of the external anal sphincter by 3-dimensional conformal fields in rectal cancer patients receiving neoadjuvant chemoradiation: implications for the concept of sphincter-preserving radiation therapy. **2014**, 2014, 578243		1
295	Anal cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. **2014**, 25 Suppl 3, iii10-20		112
294	[Sexual functions after treatment for rectal cancer: impact of doses in autonomic pelvic nerves]. *Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique*, **2014**, 18, 757-62	1.3	3
293	Rectal Cancer. *Medical Radiology*, **2014**, 303-314	0.2	
292	Anal Canal Cancer. *Medical Radiology*, **2014**, 315-325	0.2	
291	Radiation therapy of anal canal cancer: from conformal therapy to volumetric modulated arc therapy. *BMC Cancer*, **2014**, 14, 833	4.8	17
290	VMAT planning study in rectal cancer patients. *Radiation Oncology*, **2014**, 9, 219	4.2	10
289	Interstitial high-dose rate brachytherapy as boost for anal canal cancer. *Radiation Oncology*, **2014**, 9, 240	4.2	17
288	Is elective inguinal radiotherapy necessary for locally advanced rectal adenocarcinoma invading anal canal?. *Radiation Oncology*, **2014**, 9, 296	4.2	6
287	Intensity-modulated radiation therapy with concurrent chemotherapy for anal cancer: outcomes and toxicity. **2014**, 37, 461-6		49
286	Five fractions of radiation therapy followed by 4 cycles of FOLFOX chemotherapy as preoperative treatment for rectal cancer. *International Journal of Radiation Oncology Biology Physics*, **2014**, 88, 829-36	4	66
285	Decision Tools for Radiation Oncology. *Medical Radiology*, **2014**,	0.2	2
284	Therapie des Analkarzinoms. **2014**, 20, 173-182		1
283	Inguinal nodal region radiotherapy for vulvar cancer: are we missing the target again?. **2014**, 135, 583-5		4
282	Nanotechnology in radiation oncology. *Journal of Clinical Oncology*, **2014**, 32, 2879-85	2.2	41
281	Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. **2014**, 40, 1165-76		98
280	Prospective evaluation of acute toxicity and quality of life after IMRT and concurrent chemotherapy for anal canal and perianal cancer. *International Journal of Radiation Oncology Biology Physics*, **2014**, 90, 587-94	4	61
279	Consequences of anorectal cancer atlas implementation in the cooperative group setting: radiobiologic analysis of a prospective randomized in silico target delineation study. **2014**, 112, 418-24		14

278	Neoadjuvant radiation therapy prior to total mesorectal excision for rectal cancer is not associated with postoperative complications using current techniques. **2014**, 21, 2295-302		14
277	The Distribution and Patterns of Practice of Stereotactic Ablative Body Radiotherapy in Canada. **2014**, 45, 8-15		5
276	In vivo quality assurance of volumetric modulated arc therapy for ano-rectal cancer with thermoluminescent dosimetry and image-guidance. **2014**, 111, 406-11		8
275	Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. **2014**, 111, 330-9		116
274	Evaluating QUANTEC Small Bowel Dose-Volume Guidelines for Rectal Cancer Patients Treated Using a Couch Top Inclined Belly Board. **2014**, 45, 218-222		1
273	[Impact of dynamic IMRT and tomotherapy in pelvic cancers: a prospective dosimetric study with 51 patients]. *Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique*, **2014**, 18, 111-8	1.3	2
272	Intensity-modulated radiation therapy for patients with rectal cancer. **2014**, 3, 235-238		2
271	Trends in incidence and survival for anal cancer in New South Wales, Australia, 1972-2009. **2015**, 39, 842-7		25
270	WITHDRAWN: Irradiation of FDG-PET Defined-Active Bone Marrow Subregions and Acute Hematologic Toxicity in Anal Cancer Patients Undergoing Chemoradiation. *International Journal of Radiation Oncology Biology Physics*, **2015**,	4	
269	German-Austrian guidelines on anal dysplasia and anal cancer in HIV-positive individuals: prevention, diagnosis, and treatment. **2015**, 13, 1302-19		35
268	Helical tomotherapy for the treatment of anal canal cancer: a dosimetric comparison with 3D conformal radiotherapy. **2015**, 101, 268-72		8
267	Deutsch-Österreichische S2k-Leitlinie: anale Dysplasien und Analkarzinome bei HIV-Infizierten: Prävention, Diagnostik und Therapie. **2015**, 13, e1-e20		5
266	Target Volume Delineation for Conformal and Intensity-Modulated Radiation Therapy. *Medical Radiology*, **2015**,	0.2	14
265	The Role of Intensity-Modulated Radiotherapy to Optimize Outcomes in Locally Advanced Rectal Cancer. **2015**, 11, 345-351		
264	Comparison of investigator-delineated gross tumor volumes and quality assurance in pancreatic cancer: Analysis of the pretrial benchmark case for the SCALOP trial. **2015**, 117, 432-7		16
263	Locally advanced gastroesophageal junction tumor: a treatment dilemma. **2015**, 20, 134-42		4
262	The Role of FDG-PET in the Initial Staging and Response Assessment of Anal Cancer: A Systematic Review and Meta-analysis. **2015**, 22, 3574-81		75
261	Proposed genitalia contouring guidelines in anal cancer intensity-modulated radiotherapy. **2015**, 88, 20150032		8

260	Is there any impact of PET/CT on radiotherapy planning in rectal cancer patients undergoing preoperative IMRT?. **2015**, 45, 129-35		7
259	Clinical and treatment factors associated with vaginal stenosis after definitive chemoradiation for anal canal cancer. *Practical Radiation Oncology*, **2015**, 5, e113-e118	2.8	26
258	[Management of locally advanced anal canal carcinoma with modulated arctherapy and concurrent chemotherapy]. *Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique* , **2015**, 19, 127-38	1.3	2
257	CAPIRI-IMRT: a phase II study of concurrent capecitabine and irinotecan with intensity-modulated radiation therapy for the treatment of recurrent rectal cancer. *Radiation Oncology*, **2015**, 10, 57	4.2	15
256	Target Volume Definition in Radiation Oncology. **2015**,		4
255	Intensity-Modulated Radiation Therapy. **2015**,		3
254	Role of Radiotherapy and Newer Techniques in the Treatment of GI Cancers. *Journal of Clinical Oncology*, **2015**, 33, 1737-44	2.2	30
253	Clinical results and toxicity for short-course preoperative radiotherapy and total mesorectal excision in rectal cancer patients. **2015**, 56, 169-76		8
252	Nonoperative management of squamous-cell carcinoma of the rectum. **2015**, 58, 60-4		22
251	Volumetric intensity-modulated arc therapy vs. 3-dimensional conformal radiotherapy for primary chemoradiotherapy of anal carcinoma: Effects on treatment-related side effects and survival. **2015**, 191, 827-34		12
250	Dosimetric planning study for the prevention of anal complications after post-operative whole pelvic radiotherapy in cervical cancer patients with hemorrhoids. **2015**, 88, 20150223		2
249	NRG Oncology Radiation Therapy Oncology Group 0822: A Phase 2 Study of Preoperative Chemoradiation Therapy Using Intensity Modulated Radiation Therapy in Combination With Capecitabine and Oxaliplatin for Patients With Locally Advanced Rectal Cancer. *International Journal of Radiation Oncology Biology Physics*, **2015**, 93, 29-36	4	58
248	Intensity-modulated radiation therapy with simultaneous integrated boost combined with concurrent chemotherapy for the treatment of anal cancer patients: 4-year results of a consecutive case series. **2015**, 33, 259-66		36
247	Pencil-beam scanning proton therapy for anal cancer: a dosimetric comparison with intensity-modulated radiotherapy. **2015**, 54, 1209-17		22
246	[Recommendations for the management of cancers of the anal canal]. *Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique*, **2015**, 19, 416-20	1.3	0
245	Comparison of endorectal ultrasound versus pelvic magnetic resonance imaging for radiation treatment planning in locally advanced rectal cancer. *Practical Radiation Oncology*, **2015**, 5, e451-e455	2.8	3
244	Interstitial pulsed-dose-rate brachytherapy for the treatment of squamous cell anal carcinoma: A retrospective single institution analysis. **2015**, 14, 549-53		6
243	PET-based radiation therapy planning. **2015**, 10, 27-44		13

242	Dosimetric comparison of axilla and groin radiotherapy techniques for high-risk and locally advanced skin cancer. *Radiation Oncology Journal*, **2016**, 34, 145-55	2.5	7
241	Lapatinib-capecitabine versus capecitabine alone as radiosensitizers in RAS wild-type resectable rectal cancer, an adaptive randomized phase II trial (LaRRC trial): study protocol for a randomized controlled trial. **2016**, 17, 459		2
240	Pathological Assessment of Rectal Cancer after Neoadjuvant Chemoradiotherapy: Distribution of Residual Cancer Cells and Accuracy of Biopsy. **2016**, 6, 34923		8
239	Estimation of second cancer risk after radiotherapy for rectal cancer: comparison of 3D conformal radiotherapy and volumetric modulated arc therapy using different high dose fractionation schemes. *Radiation Oncology*, **2016**, 11, 149	4.2	8
238	Anal Cancer. **2016**, 357-371		4
237	Irradiation of FDG-PET-Defined Active Bone Marrow Subregions and Acute Hematologic Toxicity in Anal Cancer Patients Undergoing Chemoradiation. *International Journal of Radiation Oncology Biology Physics*, **2016**, 94, 747-54	4	21
236	Development and Validation of Consensus Contouring Guidelines for Adjuvant Radiation Therapy for Bladder Cancer After Radical Cystectomy. *International Journal of Radiation Oncology Biology Physics*, **2016**, 96, 78-86	4	31
235	Brachytherapy. *Medical Radiology*, **2016**,	0.2	4
234	[Clinical to target volume margins determination in radiotherapy for anal cancers]. *Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique*, **2016**, 20, 645-50	1.3	
233	Anal Carcinoma. **2016**, 1019-1034.e4		
232	[Radiotherapy of rectal carcinoma]. *Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique*, **2016**, 20 Suppl, S179-82	1.3	2
231	[Radiotherapy for anal canal cancers]. *Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique*, **2016**, 20 Suppl, S183-8	1.3	5
230	International consensus guidelines on Clinical Target Volume delineation in rectal cancer. **2016**, 120, 195-201		83
229	Treatment of High Rectal Cancers: Do We Need Radiation?. **2016**, 12, 266-273		1
228	Acute toxicity with intensity modulated radiotherapy versus 3-dimensional conformal radiotherapy during preoperative chemoradiation for locally advanced rectal cancer. **2016**, 121, 252-257		17
227	Correlates and trends of IMRT use in locally advanced rectal cancer. **2016**, 5, 427-435		1
226	Genital invasion or perigenital spread may pose a risk of marginal misses for Intensity Modulated Radiotherapy (IMRT) in anal cancer. *Radiation Oncology*, **2016**, 11, 53	4.2	10
225	Volumetric modulated arc therapy (VMAT) in the combined modality treatment of anal cancer patients. **2016**, 89, 20150832		31

224	Squamous-cell carcinoma of the anus: progress in radiotherapy treatment. **2016**, 13, 447-59		23
223	Rectal Radiotherapy--Intensity-modulated Radiotherapy Delivery, Delineation and Doses. **2016**, 28, 93-102		14
222	Quantitative assessment of target delineation variability for thymic cancers: Agreement evaluation of a prospective segmentation challenge. **2016**, 5, 55-61		4
221	Long-Term Bone Marrow Suppression During Postoperative Chemotherapy in Rectal Cancer Patients After Preoperative Chemoradiation Therapy. *International Journal of Radiation Oncology Biology Physics*, **2016**, 94, 1052-60	4	22
220	Proposed definition of the vaginal cuff and paracolpium clinical target volume in postoperative uterine cervical cancer. *Practical Radiation Oncology*, **2016**, 6, 5-11	2.8	9
219	Intensity-Modulated and Image-Guided Radiation Therapy. **2016**, 294-324.e5		1
218	Anal cancer FDG-PET standard uptake value: correlation with tumor characteristics, treatment response and survival. **2016**, 121, 54-9		23
217	Rectal Cancer. **2016**, 992-1018.e6		4
216	Predictors of acute toxicities during definitive chemoradiation using intensity-modulated radiotherapy for anal squamous cell carcinoma. **2016**, 55, 208-16		19
215	Small bowel protection in IMRT for rectal cancer : A´dosimetric study on supine vs. prone position. **2017**, 193, 578-588		9
214	Predictors of Radiation Therapy-Related Gastrointestinal Toxicity From Anal Cancer Dose-Painted Intensity Modulated Radiation Therapy: Secondary Analysis of NRG Oncology RTOG 0529. *International Journal of Radiation Oncology Biology Physics*, **2017**, 98, 400-408	4	21
213	Early-stage Favourable Anal Cancer: A Retrospective Analysis of Clinical Outcomes of a Moderately Low Dose Elective Nodal Intensity-modulated Radiotherapy Schedule. **2017**, 29, e105-e109		3
212	Radiotherapy for Anal Cancer: Intensity-Modulated Radiotherapy and Future Directions. **2017**, 26, 467-475		3
211	Standard fractionation external beam radiotherapy with and without intraoperative radiotherapy for locally recurrent rectal cancer: the role of local therapy in patients with a high competing risk of death from distant disease. **2017**, 90, 20170134		8
210	Improved Metastasis- and Disease-Free Survival With Preoperative Sequential Short-Course Radiation Therapy and FOLFOX Chemotherapy for Rectal Cancer Compared With Neoadjuvant Long-Course Chemoradiotherapy: Results of a Matched Pair Analysis. *International Journal of Radiation Oncology Biology Physics*, **2017**, 99, 417-426	4	48
209	Capecitabine With Mitomycin Reduces Acute Hematologic Toxicity and Treatment Delays in Patients Undergoing Definitive Chemoradiation Using Intensity Modulated Radiation Therapy for Anal Cancer. *International Journal of Radiation Oncology Biology Physics*, **2017**, 98, 1087-1095	4	31
208	Long-term outcomes and toxicities of a large cohort of anal cancer patients treated with dose-painted IMRT per RTOG 0529. **2017**, 2, 110-117		31
207	Intensity modulated radiation therapy for squamous cell carcinoma of the vulva: Treatment technique and outcomes. **2017**, 2, 148-158		21

206	Irradiation of anatomically defined pelvic subsites and acute hematologic toxicity in anal cancer patients undergoing chemoradiation. *Practical Radiation Oncology*, **2017**, 7, e291-e297	2.8	8
205	Single Nucleotide Polymorphism TGFβ1 R25P Correlates with Acute Toxicity during Neoadjuvant Chemoradiotherapy in Rectal Cancer Patients. *International Journal of Radiation Oncology Biology Physics*, **2017**, 97, 924-930	4	6
204	Management of early anal cancer: need for guidelines and standardisation. **2017**, 32, 1719-1724		3
203	Association of Coloproctology of Great Britain & Ireland (ACPGBI): Guidelines for the Management of Cancer of the Colon, Rectum and Anus (2017) - Anal Cancer. **2017**, 19 Suppl 1, 82-97		26
202	Concurrent paclitaxel, capecitabine, mitomycin C and pelvic radiation therapy for patients with squamous cell anal carcinoma. **2017**, 80, 623-629		3
201	Treatment of the Primary Tumor in Anal Canal Cancers. **2017**, 26, 73-90		10
200	Evolution and Management of Treatment-Related Toxicity in Anal Cancer. **2017**, 26, 91-113		10
199	Anal adenocarcinoma requires prophylactic inguinal nodal treatment: Results from a single Chinese institution. **2017**, 8, 1097-1102		7
198	Quality assurance of the SCOPE 1 trial in oesophageal radiotherapy. *Radiation Oncology*, **2017**, 12, 179	4.2	4
197	Clinical Target Volume Definition in Preoperative Radiotherapy of Rectal Carcinoma: a Systematic Review. **2017**, 13, 265-275		
196	Simultaneous integrated boost intensity-modulated radiotherapy versus 3-dimensional conformal radiotherapy in preoperative concurrent chemoradiotherapy for locally advanced rectal cancer. *Radiation Oncology Journal*, **2017**, 35, 208-216	2.5	9
195	Bone marrow tolerance during postoperative chemotherapy in colorectal carcinomas. *Journal of Gastrointestinal Oncology*, **2017**, 8, 547-555	2.8	2
194	Neoadjuvant Radiotherapy. **2018**, 65-76		
193	Should We Tailor the Delineation of Pelvic Structures According to Tumor Presentation?. **2018**, 165-179		
192	Which Margin Should Be Added to the GTV?. **2018**, 181-186		
191	Rapid Contour-based Segmentation for F-FDG PET Imaging of Lung Tumors by Using ITK-SNAP: Comparison to Expert-based Segmentation. **2018**, 288, 277-284		14
190	Modern intensity-modulated radiotherapy with image guidance allows low toxicity rates and good local control in chemoradiotherapy for anal cancer patients. **2018**, 144, 781-789		7
189	Lower Gastrointestinal Malignancies. **2018**, 257-269		

188	Dosimetric quantification of the incidental irradiation of the 'true' (deep) ano-inguinal lymphatic drainage of anal cancer patients not described in conventional contouring guidelines. **2018**, 57, 825-830		4
187	Carcinoma of the Anal Canal. **2018**, 335-363		
186	Toxicity, Tolerability, and Compliance of Concurrent Capecitabine or 5-Fluorouracil in Radical Management of Anal Cancer With Single-dose Mitomycin-C and Intensity Modulated Radiation Therapy: Evaluation of a National Cohort. *International Journal of Radiation Oncology Biology Physics*, **2018**, 101, 1202-1211	4	25
185	Positron emission tomography and computed tomographic (PET/CT) imaging for radiation therapy planning in anal cancer: A systematic review and meta-analysis. **2018**, 126, 6-12		14
184	Intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy in rectal cancer treated with neoadjuvant concurrent chemoradiation: a meta-analysis and pooled-analysis of acute toxicity. **2018**, 48, 458-466		16
183	Prevalence of patient-reported gastrointestinal symptoms and agreement with clinician toxicity assessments in radiation therapy for anal cancer. **2018**, 27, 97-103		9
182	Distribution of metastases in mesorectum is unpredictable: Metastases do not respect tumor localization even in small non-circumferential rectal cancers. **2018**, 44, 87-92		1
181	Neoadjuvant PET and MRI-based intensity modulated radiotherapy leads to less toxicity and improved pathologic response rates in locally advanced rectal cancer. *Journal of Gastrointestinal Oncology*, **2018**, 9, 641-649	2.8	1
180	Preoperative short course radiotherapy with concurrent and consolidation chemotherapies followed by delayed surgery in locally advanced rectal cancer: preliminary results. *Radiation Oncology Journal*, **2018**, 36, 17-24	2.5	13
179	Neoadjuvant therapy and subsequent treatment in rectal cancer: balance between oncological and functional outcomes. **2018**, 2, 47-58		2
178	Automatic Delineation of the Clinical Target Volume in Rectal Cancer for Radiation Therapy using Three-dimensional Fully Convolutional Neural Networks. **2018**, 2018, 5898-5901		5
177	A Definitive IMRT-SIB with Concomitant Chemotherapy for Synchronous Locally Advanced Anal Canal Cancer and Prostate Cancer. **2018**, 2018, 6101759		2
176	Dosimetric comparison of different radiation techniques (IMRT vs. 3-dimensional) of the "true" (deep) ano-inguinal lymphatic drainage of anal cancer patients. *Radiation Oncology*, **2018**, 13, 227	4.2	2
175	Impact of VMAT-IMRT compared to 3D conformal radiotherapy on anal sphincter dose distribution in neoadjuvant chemoradiation of rectal cancer. *Radiation Oncology*, **2018**, 13, 237	4.2	7
174	Dosimetric analysis and comparison of reduced longitudinal cranial margins of VMAT-IMRT of rectal cancer. *Radiation Oncology*, **2018**, 13, 169	4.2	2
173	Prognostic markers of recurrence and survival in rectal cancer treated with neoadjuvant chemoradiotherapy and surgery. **2018**, 7, CRC02		3
172	Quality Control of Radiation Delivery for Lower Gastrointestinal Cancers. **2018**, 19, 51		1
171	Prospective study of neoadjuvant chemoradiotherapy using intensity-modulated radiotherapy and 5 fluorouracil for locally advanced rectal cancer - toxicities and response assessment. **2018**, 10, 519-526		5

170	Anal Cancer. **2018**, 515-531		
169	A˝treatment planning study of prone vs. supine positions for locally advanced rectal carcinoma : Comparison of 3-dimensional conformal radiotherapy, tomotherapy, volumetric modulated arc therapy, and intensity-modulated radiotherapy. **2018**, 194, 975-984		5
168	Conformal Radiotherapy: Simulation and Contouring. **2018**, 109-137		
167	Variability of clinical target volume delineation for rectal cancer patients planned for neoadjuvant radiotherapy with the aid of the platform Anatom-e. **2018**, 11, 33-39		11
166	Definitive chemoradiotherapy for anal canal cancer: single-center experience. **2018**, 23, 1121-1126		3
165	Hybrid Tri-Co-60 MRI radiotherapy for locally advanced rectal cancer: An evaluation. **2018**, 6, 5-10		11
164	Management of locally advanced anal canal carcinoma with intensity-modulated radiotherapy and concurrent chemotherapy. **2018**, 35, 134		2
163	Radiation Therapy in Rectal Cancer. **2018**, 1-21		
162	Excluding the ischiorectal fossa irradiation during neoadjuvant chemoradiotherapy with intensity-modulated radiotherapy followed by abdominoperineal resection decreases perineal complications in patients with lower rectal cancer. *Radiation Oncology*, **2019**, 14, 138	4.2	1
161	Anal Cancer. **2019**,		
160	Have we achieved adequate recommendations for target volume definitions in anal cancer? A PET imaging based patterns of failure analysis in the context of established contouring guidelines. *BMC Cancer*, **2019**, 19, 742	4.8	13
159	High-dose-rate vs. low-dose-rate interstitial brachytherapy boost for anal canal cancers. **2019**, 18, 814-822		1
158	Outcomes after intensity-modulated compared with 3-dimensional conformal radiotherapy with chemotherapy for squamous cell carcinoma of the anal canal. **2019**, 26, e515-e521		2
157	mARC preoperative rectal cancer treatments vs. 3D conformal radiotherapy. A dose distribution comparative study. **2019**, 14, e0221262		1
156	Executive Summary of the American Radium Society Appropriate Use Criteria for Treatment of Anal Cancer. *International Journal of Radiation Oncology Biology Physics*, **2019**, 105, 591-605	4	2
155	18F-FDG PET Predicts Hematologic Toxicity in Patients with Locally Advanced Anal Cancer Treated With Chemoradiation. **2019**, 4, 613-622		4
154	[Anal channel cancer: customization of dose, volume and breaching]. *Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique*, **2019**, 23, 773-777	1.3	
153	A systematic review and meta-analysis of pT2 rectal cancer spread and recurrence pattern: Implications for target design in radiation therapy for organ preservation. **2019**, 133, 20-27		6

152	Intensity-modulated radiotherapy at high-volume centers improves survival in patients with esophageal adenocarcinoma receiving trimodality therapy. **2019**, 32,		3
151	Radiation Oncology. **2019**,		2
150	Impact of pelvic bone marrow irradiation on the hematological toxicity of subsequent chemotherapy in rectal cancer. **2019**, 66, 276-280		0
149	Anti-epidermal growth factor receptor therapy in combination with chemoradiotherapy for the treatment of locally advanced anal canal carcinoma: Results of a phase I dose-escalation study with panitumumab (FFCD 0904). **2019**, 140, 84-89		5
148	The Management and Prevention of Anal Squamous Cell Carcinoma. **2019**, 39, 216-225		11
147	Neoadjuvant chemoradiotherapy delivered with helical tomotherapy under daily image guidance for rectal cancer patients: efficacy and safety in a large, multi-institutional series. **2019**, 145, 1075-1084		2
146	Positron emission tomography with computed tomography imaging (PET/CT) for the radiotherapy planning definition of the biological target volume: PART 2. **2019**, 139, 117-124		12
145	Radiation-induced injury on surgical margins: a clue to anastomotic leakage after rectal-cancer resection with neoadjuvant chemoradiotherapy?. **2019**, 7, 98-106		13
144	Induction Chemotherapy Reduces Patient-reported Toxicities During Neoadjuvant Chemoradiation with Intensity Modulated Radiotherapy for Rectal Cancer. *Clinical Colorectal Cancer*, **2019**, 18, 167-174	3.8	2
143	An quality assurance study of contouring target volumes in thoracic tumors within a cooperative group setting. **2019**, 15, 83-92		2
142	Anal Cancer in the Era of Dose Painted Intensity Modulated Radiation Therapy: Implications for Regional Nodal Therapy. *Seminars in Radiation Oncology*, **2019**, 29, 137-143	5.5	
141	Cancer of the anal region. **2019**, 135, 115-127		21
140	Intensity-modulated radiation therapy of anal squamous cell carcinoma: Relationship between delineation quality and regional recurrence. **2019**, 131, 93-100		6
139	To what extent should the intestinal be resected proximally after radiotherapy: hint from a pathological view. **2020**, 8, 277-285		2
138	The importance of mesorectum motion in determining PTV margins in rectal cancer patients treated with neoadjuvant radiotherapy. **2020**, 61, 335-342		1
137	Long-term follow-up experience in anal canal cancer treated with Intensity-Modulated Radiation Therapy: Clinical outcomes, patterns of relapse and predictors of failure. **2020**, 144, 141-147		11
136	Effect of prone and supine treatment positions for postoperative treatment of rectal cancer on target dose coverage and small bowel sparing using intensity-modulated radiation therapy.. **2020**, 9, 491-499		2
135	Bone Marrow-Sparing IMRT in Anal Cancer Patients Undergoing Concurrent Chemo-Radiation: Results of the First Phase of a Prospective Phase II Trial. *Cancers*, **2020**, 12,	6.6	10

134	Dose-volume parameters of MRI-based active bone marrow predict hematologic toxicity of chemoradiotherapy for rectal cancer. **2020**, 196, 998-1005		3
133	Evaluation of small bowel motion and feasibility of using the peritoneal space to replace bowel loops for dose constraints during intensity-modulated radiotherapy for rectal cancer. *Radiation Oncology*, **2020**, 15, 211	4.2	0
132	Oral contrast agents lead to underestimation of dose calculation in volumetric-modulated arc therapy planning for pelvic irradiation. **2020**, 133, 2061-2070		2
131	Patterns of inguinal lymph node metastases in anal canal cancer and recommendations for elective clinical target volume (CTV) delineation. **2020**, 149, 128-133		4
130	Patterns of recurrence in anal cancer: a detailed analysis. *Radiation Oncology*, **2020**, 15, 125	4.2	10
129	Dosimetric comparison of organs at risk using different contouring guidelines for definition of the clinical target volume in anal cancer. **2020**, 196, 368-375		1
128	Re-irradiation for recurrent rectal cancer - a single-center experience. **2020**, 59, 534-540		0
127	Adding Boost to Standard Neoadjuvant Radiation for Rectal Cancer Improves Likelihood of Complete Response. **2020**, 24, 1655-1662		
126	What is the Best Way to Plan Rectum Three-Dimensional Conformal Radiotherapy in Prone Position-Classic Anatomical Landmark, Three Dimensional Fitting the Planning Target Volume, or Volumetric Modulated´Arc?. **2020**, 51, 103-107		
125	Automatic segmentation software in locally advanced rectal cancer: READY (REsearch program in Auto Delineation sYstem)-RECTAL 02: prospective study. *Oncotarget*, **2016**, 7, 42579-42584	3.3	11
124	Rare Genitourinary Malignancies (Penile, Urethral, Renal Pelvis, and Ureteral Cancers). **2021**, 313-362		
123	The Distribution of Pelvic Nodal Metastases in Prostate Cancer Reveals Potential to Advance and Personalize Pelvic Radiotherapy. *Frontiers in Oncology*, **2020**, 10, 590722	5.3	2
122	Pulse-dose-rate interstitial brachytherapy in anal squamous cell carcinoma: clinical outcomes and patients' health quality perception. **2021**, 13, 263-272		0
121	[Pelvic irradiation and hematopoietic toxicity: A review of the literature]. *Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique*, **2021**, 25, 77-91	1.3	2
120	Cisplatin/capecitabine with intensity-modulated radiation therapy in anal squamous cell carcinoma: a preliminary study. **2021**, 56, 432-436		3
119	Interobserver variability in clinical target volume delineation in anal squamous cell carcinoma. **2021**, 11, 2785		0
118	Quality indicator selection for the Canadian Partnership against Cancer rectal cancer project: A modified Delphi study. **2021**, 23, 1393-1403		1
117	Evolution of the Role of Radiotherapy for Anal Cancer. *Cancers*, **2021**, 13,	6.6	5

116	Radiotherapy with Intensity-Modulated (IMRT) Techniques in the Treatment of Anal Carcinoma (RAINSTORM): A Multicenter Study on Behalf of AIRO (Italian Association of Radiotherapy and Clinical Oncology) Gastrointestinal Study Group. *Cancers*, **2021**, 13,	6.6	0
115	Anorectal function and radiation dose to pelvic floor muscles after primary treatment for anal cancer. **2021**, 157, 141-146		0
114	Patterns of pathologic lymph nodes in anal cancer: a PET-CT-based analysis with implications for radiotherapy treatment volumes. *BMC Cancer*, **2021**, 21, 447	4.8	
113	Method of computing direction-dependent margins for the development of consensus contouring guidelines. *Radiation Oncology*, **2021**, 16, 71	4.2	1
112	Sexual organ-sparing with hydrogel spacer injections for rectal cancer radiotherapy: a feasibility pilot study. **2021**, 94, 20200931		1
111	Effect of Pelvic Bone Marrow Sparing Intensity Modulated Radiation Therapy on Acute Hematologic Toxicity in Rectal Cancer Patients Undergoing Chemo-Radiotherapy. *Frontiers in Oncology*, **2021**, 11, 646211	5.3	1
110	Concurrent Chemoradiation in Anal Cancer Patients Delivered with Bone Marrow-Sparing IMRT: Final Results of a Prospective Phase II Trial. **2021**, 11,		2
109	Intensity modulated radiotherapy for anal canal squamous cell carcinoma: A 16-year single institution experience. **2021**, 28, 17-23		1
108	Mutation in a Patient With Early Rectal Cancer Receiving Definitive Chemoradiation. **2021**, 6, 100717		1
107	Volumetric Modulated Arc Therapy Improves Outcomes in Definitive Radiochemotherapy for Anal Cancer Whilst Reducing Acute Toxicities and Increasing Treatment Compliance. *Cancers*, **2021**, 13,	6.6	1
106	What is the optimal treatment for T1N0 anal squamous cell carcinoma? Analysis of current practices in the prospective French FFCD ANABASE cohort. **2021**, 53, 776-784		1
105	Value of PET imaging for radiation therapy. **2021**, 60, 326-343		0
104	Value of PET imaging for radiation therapy. **2021**, 197, 1-23		1
103	FDG-PET/CT in the Radiotherapy Treatment Planning of Locally Advanced Anal Cancer: A Monoinstitutional Experience. *Frontiers in Oncology*, **2021**, 11, 655322	5.3	0
102	Sarcopenia and dosimetric parameters in relation to treatment-related leukopenia and survival in anal cancer. *Radiation Oncology*, **2021**, 16, 152	4.2	2
101	Effective Organs-at-Risk Dose Sparing in Volumetric Modulated Arc Therapy Using a Half-Beam Technique in Whole Pelvic Irradiation. *Frontiers in Oncology*, **2021**, 11, 611469	5.3	0
100	Patterns of failure and implications for clinical target volume definition of locally advanced T4b rectal cancer identified with magnetic resonance imaging and treated using neoadjuvant chemoradiotherapy and surgery. **2021**, 161, 132-139		0
99	Long-Term Outcomes of NRG Oncology/RTOG 0529: A Phase 2 Evaluation of Dose-Painted Intensity Modulated Radiation Therapy in Combination With 5-Fluorouracil and Mitomycin-C for the Reduction of Acute Morbidity in Anal Canal Cancer. *International Journal of Radiation Oncology Biology Physics*, **2021**,	4	3

98	Dosimetric and Clinical Predictors for Acute and Late Gastrointestinal Toxicity Following Chemoradiotherapy of Locally Advanced Anal Cancer. **2021**,		0
97	Treatment of Squamous Cell Carcinoma of the Anus, Unresolved Areas and Future Perspectives for Research: Perspectives of Research Needs in Anal Cancer. *Clinical Colorectal Cancer*, **2021**,	3.8	2
96	Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. **2021**, 32, 1087-1100		13
95	Optimization of Field Design in the Treatment of Rectal Cancer with Intensity Modulated Proton Beam Radiation Therapy: How Many Fields Are Needed to Account for Rectal Distension Uncertainty?. **2021**, 6, 100749		1
94	FIELD: an open-source platform for the assessment of target volume delineation in radiation therapy. **2021**, 94, 20210356		
93	Cancer theranostic platforms based on injectable polymer hydrogels. **2021**, 9, 3543-3575		4
92	Anal Cancer. **2010**, 395-407		2
91	Rectal and Colon Cancer: Radiation Therapy Planning. **2017**, 171-180		1
90	Anal Carcinoma. **2015**, 193-218		2
89	Cancer of the Uterine Cervix. **2010**, 1002-1025		0
88	PET-CT guided SIB-IMRT combined with concurrent 5-FU/MMC for the treatment of anal cancer. **2017**, 56, 1734-1740		12
87	Volumetric modulated arc therapy (VMAT) in the combined modality treatment of anal cancer patients. **2016**, 89, 20160832		6
86	Associations of tumor regression grade with outcomes in patients with locally advanced rectal cancer treated with preoperative two-week course of radiotherapy. *Oncotarget*, **2017**, 8, 100165-100175	3.3	1
85	Predictive value of APAF-1 and COX-2 expression in pathologic complete response to neoadjuvant chemoradiotherapy for patients with locally advanced rectal adenocarcinoma. *Oncotarget*, **2016**, 7, 35233-40	3.3	11
84	Dosimetric advantages and clinical outcomes of simultaneous integrated boost intensity-modulated radiotherapy for anal squamous cell carcinoma. *Radiation Oncology Journal*, **2017**, 35, 368-379	2.5	12
83	Short-course versus long-course neoadjuvant chemoradiotherapy in patients with rectal cancer: preliminary results of a randomized controlled trial. *Radiation Oncology Journal*, **2020**, 38, 119-128	2.5	6
82	Technical aspects of radiation therapy for anal cancer. *Journal of Gastrointestinal Oncology*, **2014**, 5, 198-211	2.81	13
81	Comparison of bone marrow sparing intensity modulated radiotherapy (IMRT) and three-dimensional conformal radiotherapy (3DCRT) in carcinoma of anal canal: a prospective study. *Annals of Translational Medicine*, **2016**, 4, 70	3.2	4

80	Five-year outcomes of preoperative chemoradiation for rectal carcinoma in Saudi population: single-institutional experience. *Annals of Saudi Medicine*, **2015**, 35, 23-30	1.6	1
79	Is elective inguinal or external iliac irradiation during neoadjuvant (chemo)radiotherapy necessary for locally advanced lower rectal cancer with anal sphincter invasion?. *Practical Radiation Oncology*, **2021**,	2.8	0
78	Efficacy and safety of sequential neoadjuvant chemotherapy and short-course radiation therapy followed by delayed surgery in locally advanced rectal cancer: a single-arm phase II clinical trial with subgroup analysis between the older and young patients.. *Radiation Oncology Journal*, **2021**, 39, 270-278	2.5	1
77	Long-term Patterns of Failure and the Value of Blood Prognostic Markers in Anal Cancers Treated With Intensity-Modulated Radiation Therapy. *Clinical Colorectal Cancer*, **2021**,	3.8	
76	Three-Dimensional Conformal Radiotherapy and Intensity-Modulated Radiotherapy. **2010**, 170-192		
75	Anal Carcinoma. **2012**, 1017-1031		
74	Rectal Cancer. **2012**, 989-1015		0
73	What Are the Dose-Volume Constraints to Reduce Late Toxicity?. **2012**, 149-154		
72	Conformal Therapy and Intensity-Modulated Radiation Therapy. **2012**, 287-316		0
71	Analkarzinom. **2013**, 689-701		
70	Cancer of the Rectum. **2014**, 1336-1359.e8		
69	Imagerie post-thérapeutique du cancer du rectum. **2014**, 119-135		
68	Therapie des Analkarzinoms. **2015**, 135-142		
67	Postoperative Chemoradiation for Rectal Cancer. **2015**, 241-257		
66	Radiation Therapy in the Treatment of Rectal Cancer. **2015**, 503-510		
65	Anal Canal Cancer. **2015**, 337-354		
64	Rectal Cancer. **2015**, 169-191		
63	Anal Canal Cancer: Pathophysiology, Diagnosis and Treatment. **2015**, 305-316		

62	Gynecological Cancer. **2015**, 301-322		
61	Dosimetric Comparison of Volumetric Modulated Arc Therapy (VMAT), 5F Intensity Modulated Radiotherapy (IMRT) and 3D Conformal Radiotherapy (3DCRT) in Rectal Carcinoma Receiving Neoadjuvant Chemoradiotherapy. *International Journal of Medical Physics, Clinical Engineering and Radiation Oncology*, **2015**, 04, 54-63	0.1	2
60	Anus. 327-332		
59	Lower Gastrointestinal Brachytherapy: Anus. *Medical Radiology*, **2016**, 353-364	0.2	
58	Anal Cancer: Radiation Therapy Planning. **2017**, 201-215		
57	Anal Cancer: Background and Clinical Evidence. **2017**, 181-200		
56	Anus. 327-332		
55	Pelvic recurrence after definitive surgery for locally advanced rectal cancer: a retrospective investigation of implications for precision radiotherapy field design. *Oncotarget*, **2017**, 8, 95973-95980	3.3	
54	Radiation Therapy in Anal Cancer. **2018**, 1-23		
53	How Histopathologic Tumor Extent and Patterns of Recurrence Data Inform the Development of Radiation Therapy Treatment Volumes in Solid Malignancies. *Seminars in Radiation Oncology*, **2018**, 28, 218-237	5.5	
52	Preserving Fertility in Patients with Gastrointestinal Cancers. **2019**, 633-653		
51	Gastrointestinal System Cancers. **2019**, 197-268		
50	Radiation Therapy: The North American Approach. **2019**, 365-403		1
49	Treatment of Localized Anal Cancer: Chemoradiotherapy. **2019**, 47-70		
48	Intensification of Radiation Therapy with Control of the Amount of Radiation Using MRI in Patients with Squamous Cell Carcinoma of the Anal Canal. *Medical Alphabet*, **2019**, 2, 32-37	0.3	
47	Evolving Concepts toward Individualized Treatment of Squamous Cell Carcinoma of the Anus.		
46	Radiotherapy of Squamous Cell Carcinoma of the Anal Canal: Search for Optimal Solutions. *Journal of Oncology Diagnostic Radiology and Radiotherapy*, **2020**, 3, 19-30	0.1	
45	Radiotherapy in Early-Stage and Local Advanced Rectal Cancer. **2021**, 663-682		

44	Impact of IMRT- and VMAT technologies on selection of total dose of radiation therapy in patients with squamous cell carcinoma of anal canal. *Medical Alphabet*, **2020**, 13-20	0.3	
43	Predictors of acute gastrointestinal toxicity during pelvic chemoradiotherapy in patients with rectal cancer. *Gastrointestinal Cancer Research: GCR*, **2013**, 6, 129-36		12
42	Acute gastrointestinal toxicity and tumor response with preoperative intensity modulated radiation therapy for rectal cancer. *Gastrointestinal Cancer Research: GCR*, **2013**, 6, 137-43		24
41	Protons offer reduced bone marrow, small bowel, and urinary bladder exposure for patients receiving neoadjuvant radiotherapy for resectable rectal cancer. *Journal of Gastrointestinal Oncology*, **2014**, 5, 3-8	2.8	20
40	Dosimetric Comparison between Intensity Modulated Radiotherapy and 3 Dimensional Conformal Radiotherapy in the Treatment of Rectal Cancer. *Asian Pacific Journal of Cancer Prevention*, **2016**, 17, 4935-4937	1.7	2
39	Current treatment and future directions in the management of anal cancer. *Ca-A Cancer Journal for Clinicians*, **2021**,	220.7	2
38	A blind randomized validated convolutional neural network for auto-segmentation of clinical target volume in rectal cancer patients receiving neoadjuvant radiotherapy. *Cancer Medicine*, **2021**,	4.8	2
37	C-Reactive Protein as Predictive Biomarker for Response to Chemoradiotherapy in Patients with Locally Advanced Rectal Cancer: A Retrospective Study.. *Cancers*, **2022**, 14,	6.6	1
36	Radiotherapy of anal canal cancer.. *Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique*, **2021**,	1.3	0
35	Rectal cancer radiotherapy.. *Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique*, **2021**,	1.3	0
34	Lateral Lymph Nodes in Rectal Cancer: Do we all Think the Same? A Review of Multidisciplinary Obstacles and Treatment Recommendations.. *Clinical Colorectal Cancer*, **2022**,	3.8	0
33	Multicenter, Randomized, Phase III Trial of Short-Term Radiotherapy Plus Chemotherapy Versus Long-Term Chemoradiotherapy in Locally Advanced Rectal Cancer (STELLAR).. *Journal of Clinical Oncology*, **2022**, JCO2101667	2.2	11
32	Characteristics of anal canal cancer in Japan.. *Cancer Medicine*, **2022**,	4.8	1
31	Compliance to chemoradiation in squamous cell carcinoma of the anus.. *Cancer Treatment Reviews*, **2022**, 106, 102381	14.4	
30	Pilot trial of topical MTS-01 application to reduce dermatitis in patients receiving chemoradiotherapy for stage I-III carcinoma of the anal canal.. *International Journal of Oncology*, **2022**, 60,	1	
29	Analysis of Clinicopathological Factors Associated with Radiation-Induced Cystitis in Patients with Cervical Cancer. *Journal of Healthcare Engineering*, **2022**, 2022, 1-10	3.7	
28	Evaluation of the ITV-margin and variables affecting bladder and mesorectal deformation during long course neoadjuvant radiotherapy for rectal cancer.. *Medical Dosimetry*, **2022**,	1.3	
27	Table_1.docx. **2021**,		

26	Video_1.mp4. **2021**,		
25	Improving the accuracy and consistency of clinical target volume delineation for rectal cancer by an education program. *World Journal of Gastrointestinal Oncology*, **2022**, 14, 1027-1036	3.4	
24	Protective ileostomy increased the incidence of rectal stenosis after anterior resection for rectal cancer.. *Radiation Oncology*, **2022**, 17, 93	4.2	
23	Anal Cancer: Emerging Standards in a Rare Rare Disease. *Journal of Clinical Oncology*,	2.2	1
22	Correcting rotational error in rectal cancer radiation therapy: Can planning target volume margins be safely reduced?. *Journal of Medical Radiation Sciences*,	1.5	
21	Overview of Radiation Treatment Volume Variations in Anal Cancer Contouring Guidelines. *Practical Radiation Oncology*, **2022**,	2.8	
20	Necessity of external iliac lymph nodes and inguinal nodes radiation in rectal cancer with anal canal involvement. *BMC Cancer*, **2022**, 22,	4.8	
19	ECOG-ACRIN Guideline for Contouring and Treatment of Early Stage Anal Cancer Using IMRT/IGRT. *Practical Radiation Oncology*, **2022**, 12, 335-347	2.8	0
18	Early results from implementation of a watch and wait protocol for complete clinical response following chemoradiotherapy for rectal cancer. *ANZ Journal of Surgery*,	1	0
17	CT-Only Radiotherapy: An Exploratory Study for Automatic Dose Prediction on Rectal Cancer Patients Via Deep Adversarial Network. *Frontiers in Oncology*, 12,	5.3	
16	Histopathological and Haemogram Features Correlate with Prognosis in Rectal Cancer Patients Receiving Neoadjuvant Chemoradiation without Pathological Complete Response. **2022**, 11, 4947		
15	The Kinetics of FMS-Related Tyrosine Kinase 3 Ligand (Flt-3L) during Chemoradiotherapy Suggests a Potential Gain from the Earlier Initiation of Immunotherapy. **2022**, 14, 3844		0
14	Anal Cancer. **2022**, 235-249		0
13	Rectal Cancer. **2022**, 217-234		0
12	Pelvic insufficiency fractures and bone pain after radiotherapy for anal cancer -Relation to pelvic bone dose volume parameters.. **2022**, 101110		0
11	Anal squamous cell carcinoma: Impact of radiochemotherapy evolution over years and an explorative analysis of MRI prediction of tumor response in a mono-institutional series of 131 patients. 12,		0
10	Deep learning empowered volume delineation of whole-body organs-at-risk for accelerated radiotherapy. **2022**, 13,		0
9	Comparación clínica de radioterapia de intensidad modulada versus radioterapia 3D en tratamiento neoadyuvante del cáncer de recto localmente avanzado. **2018**, 23,		0

8	Advances in the treatment of anal squamous cell cancer. **2022**, 16, 317-321	0
7	Inguinal nodal clinical target volume delineation based on analysis of anatomical locations of normal and metastatic lymph nodes in pelvic malignant tumors. **2023**, 183, 109634	0
6	Implications of recent neoadjuvant clinical trials on the future practice of radiotherapy in locally advanced rectal cancer. 29, 1011-1025	0
5	Radiation hematologic toxicity prediction for locally advanced rectal cancer using dosimetric and radiomics features.	0
4	Impact of dose escalation on colostomy-free survival and treatment outcome in squamous cell anal carcinoma.	0
3	Excluding external iliac node irradiation during neoadjuvant radiotherapy decreases lower intestinal toxicity without compromising efficacy in T4b rectal cancer patients with tumours involving the anterior structures.	0
2	Neoadjuvant short-course radiotherapy followed by consolidation chemotherapy versus long-course chemoradiotherapy in locally advanced rectal cancer: comparison of overall response rates.	0
1	Identification of patients with locally advanced rectal cancer eligible for neoadjuvant chemotherapy alone: Results of a retrospective study.	0